Study To antagOnize Plasminogen Activator Inhibitor-1 in Severe COVID-19

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2020
This is a single-center, randomized double blind placebo controlled trial to evaluate the efficacy and safety of novel PAI-1 inhibitor (TM5614) for high-risk patients hospitalized with severe COVID-19 at Northwestern Memorial Hospital. The patients will be randomized in a 1:1 ratio to receive standard of care plus TM5614 or standard of care plus placebo.
Epistemonikos ID: aa2746503c8c98d4c794dd931c07c4460dee920e
First added on: Nov 19, 2020